Black Diamond Therapeutics, Inc. (BDTX) News
Follow Black Diamond Therapeutics, Inc. (BDTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BDTX: Silevertinib delivers best-in-class CNS efficacy and broad mutation coverage in NSCLC and GBM
Silevertinib shows strong efficacy and CNS activity in NSCLC with non-classical EGFR mutations, outperforming competitors in both mutation coverage and brain penetrance. Regulatory discussions are underway for a pivotal
NEWS | Sep 15, 2026, 04:15 PM UTC
L
BDTX: Silevertinib delivers best-in-class CNS efficacy in non-classical EGFR-mutated NSCLC, with pivotal trials advancing
Silevertinib shows strong efficacy and CNS activity in non-classical EGFR-mutated NSCLC, with a 60% response rate and 86% CNS response, and is advancing in both NSCLC and GBM. FDA feedback on pivotal trial design is expe
CENTRAL_BANK | Sep 15, 2026, 03:54 PM UTC
L
BDTX - Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
BDTX - Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 02, 2026, 08:01 PM UTC
L
BDTX - Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BDTX - Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 05, 2026, 08:01 PM UTC